Upregulation of IL-2Ra, MIF, and IL-17A was observed for all RRMS cases; however, these cytokines did not significantly differ between newly diagnosed MS cases and controls (Table 2, Figure 2). This evidence concerns the gene IL2RA and relapsing-remitting multiple sclerosis.